Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).

Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis. Medicine (Baltimore) (2015) 0.75

Stroke: The question of alteplase dose for stroke is not resolved. Nat Rev Neurol (2016) 0.75

Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial. Stroke Vasc Neurol (2017) 0.75

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66

Autophagy regulates lipid metabolism. Nature (2009) 13.33

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01

Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ (2010) 4.74

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 4.19

Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14

Autophagy regulates adipose mass and differentiation in mice. J Clin Invest (2009) 3.95

Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke (2011) 3.94

Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation (2013) 3.57

Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature (2008) 3.44

Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21

Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology (2009) 2.78

JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology (2006) 2.70

Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature (2012) 2.67

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost (2011) 2.53

The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43

The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol Pharmacol (2009) 2.30

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke (2008) 2.24

Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol (2010) 2.12

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol (2008) 2.07

Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke (2011) 1.91

Regulation of adipogenesis by natural and synthetic REV-ERB ligands. Endocrinology (2010) 1.88

Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem (2005) 1.80

Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75

Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke (2012) 1.73

Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke (2009) 1.72

Conditional activation of β-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum (2012) 1.67

Intravenous alteplase for stroke in those older than 80 years old. Stroke (2010) 1.65

Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke (2007) 1.62

DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol (2011) 1.59

Higher prehospital priority level of stroke improves thrombolysis frequency and time to stroke unit: the Hyper Acute STroke Alarm (HASTA) study. Stroke (2012) 1.57

Trends in Door-to-Thrombolysis Time in the Safe Implementation of Stroke Thrombolysis Registry: Effect of Center Volume and Duration of Registry Membership. Stroke (2015) 1.54

Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med (2008) 1.54

Neurothrombectomy for the treatment of acute ischemic stroke: results from the TREVO study. Cerebrovasc Dis (2013) 1.53

Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke (2010) 1.53

Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008). Med J Aust (2010) 1.47

Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke (2009) 1.44

BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development. J Cell Sci (2011) 1.44

Neuroprotection in cerebral ischaemia: facts and fancies--the need for new approaches. Cerebrovasc Dis (2004) 1.42

F-wave latencies in patients with diabetes mellitus. Muscle Nerve (2014) 1.42

Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg? Stroke (2011) 1.41

Metabolic control of oocyte apoptosis mediated by 14-3-3zeta-regulated dephosphorylation of caspase-2. Dev Cell (2009) 1.41

Thrombolysis in stroke despite contraindications or warnings? Stroke (2013) 1.40

Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis. Stroke (2013) 1.40

Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke (2011) 1.37

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res (2013) 1.36

Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. J Biol Chem (2010) 1.36

Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol (2010) 1.34

Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke (2006) 1.31

Factors influencing in-hospital delay in treatment with intravenous thrombolysis. Stroke (2012) 1.26

Oxidant-induced hepatocyte injury from menadione is regulated by ERK and AP-1 signaling. Hepatology (2003) 1.20

Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage: a prospective study of 139 cases. Stroke (2011) 1.18

Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke (2009) 1.18

Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A (2014) 1.16

Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS Chem Biol (2010) 1.14

Hyperdense middle cerebral artery sign on admission CT scan--prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the safe implementation of thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis (2008) 1.13

miR-182 inhibits Schwann cell proliferation and migration by targeting FGF9 and NTM, respectively at an early stage following sciatic nerve injury. Nucleic Acids Res (2012) 1.12

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12

A statistical model for the dependence between progression-free survival and overall survival. Stat Med (2009) 1.08

Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev (2013) 1.07

Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm (2009) 1.07

Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol (2010) 1.07

Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials (2012) 1.06

Early changes of microRNAs expression in the dorsal root ganglia following rat sciatic nerve transection. Neurosci Lett (2011) 1.06

Stroke: working toward a prioritized world agenda. Stroke (2010) 1.05

Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study. JAMA Neurol (2013) 1.05

Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma. Dig Dis Sci (2010) 1.05

MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell (2013) 1.05

Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke (2013) 1.05

Differential gene expression profiling and biological process analysis in proximal nerve segments after sciatic nerve transection. PLoS One (2013) 1.05

Novel risk score to predict pneumonia after acute ischemic stroke. Stroke (2013) 1.04

Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke (2012) 1.02

Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation. Int J Pharm (2009) 1.02

miR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 after sciatic nerve injury. J Cell Sci (2012) 1.02

3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J (2006) 1.02

Stroke: working toward a prioritized world agenda. Cerebrovasc Dis (2010) 1.01

Comparison of different anthropometric measures as predictors of diabetes incidence in a Chinese population. Diabetes Res Clin Pract (2011) 1.01

On the variability of covariate adjustment. experience with Koch's method for evaluating the absolute difference in proportions in randomized clinical trials. Control Clin Trials (2002) 1.01

Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol (2013) 1.00

microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection. PLoS One (2012) 1.00

Abnormal glucose regulation in patients with acute stroke across China: prevalence and baseline patient characteristics. Stroke (2012) 1.00

Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register. Stroke (2013) 0.99